

10/646,625

~~10634423~~

1/27/06

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/Caplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/Caplus with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:57:54 ON 30 JAN 2006

=> file reg

Page 1 saeed

10/646, 625

10631423

1/27/06

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:58:06 ON 30 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2006 HIGHEST RN 872967-60-7

DICTIONARY FILE UPDATES: 29 JAN 2006 HIGHEST RN 872967-60-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10646625.str



chain nodes :

6 7 8 9 12 13 14 15

ring nodes :

1 2 3 4 5

chain bonds :

~~10601423~~

1/27/06

1-6 3-13 6-7 7-8 8-9 9-12 13-14 13-15

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 1-6 8-9 9-12 13-14 13-15

exact bonds :

2-3 3-4 3-13 4-5 6-7 7-8

isolated ring systems :

containing 1 :

G1:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 12:Atom
13:CLASS 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:58:26 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 155 TO ITERATE

100.0% PROCESSED 155 ITERATIONS

17 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2354 TO 3846

PROJECTED ANSWERS: 93 TO 587

L2 17 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 10:58:43 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2831 TO ITERATE

~~10001423~~

1/27/06

100.0% PROCESSED 2831 ITERATIONS
SEARCH TIME: 00.00.01

263 ANSWERS

L3 263 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 10:58:50 ON 30 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2006 VOL 144 ISS 6

FILE LAST UPDATED: 29 Jan 2006 (20060129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 19 L3

=> d ibib abs hitstr tot

10633403

1/27/06

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:954032 CAPLUS
 DOCUMENT NUMBER: 143:248280
 TITLE: Preparation of pyrrole derivatives as factor Xa inhibitors
 INVENTOR(S): Bauer, Armin; Wagner, Michael; Nazare, Marc; Wehner, Volkmar; Urmann, Matthias; Matter, Hans
 PATENT ASSIGNER(S): Aventis Pharma Deutschland G.m.b.H., Germany
 SOURCE: Eur. Pat. Appl., 94 pp.
 CODEN: EPXKDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1568698	A1	20050831	EP 2004-4503	20040227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005085239	A2	20050915	WO 2005-EP1423	20050212
WO 2005085239	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: BW, GH, GM, KE, LS, MW, NG, NA, SD, SL, SZ, TZ, UG, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: EP 2004-4503 A 20040227				
OTHER SOURCE(S): MARPAT 143:248280				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I and II [R = (un)substituted, mono- or bicyclic 6-14 membered aryl or 4-15 membered heterocycle; Q = a bond, SO₂, alkylene, etc.; R₁ = H, perfluoroalkylene, (un)substituted alkyl, etc. or R₁ and R₅ together form 6-8 membered (un)substituted heterocycle; R₂ = a bond or alkylene; R₁-R₂-V can form 4-8 membered (un)substituted heterocycle; V = (un)substituted 3-7 membered heterocycle, 6-14 membered aryl or 4-15 membered heterocycle; G = a bond, (CH₂)_m-O-(CH₂)_n, (CH₂)₅-(CH₂)_n, etc.; n and m independently = 0-6; M = H, (un)substituted alkyl, cycloalkyl, etc.; R₃, R₄ and R₅ independently = H, halo, perfluoroalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of factor Xa. Thus, e.g., III was prepared by coupling of 1H-pyrrole-2-carboxylic acid Et ester with 3-bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole followed by hydrolysis and amination with 1-isopropyl-piperidin-4-ylamine dihydrochloride. The activity of I and II

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 was evaluated using chromogenic enzyme assays and it was revealed that compds. of the invention display K_i values for inhibition factor Xa in the range of 0.059 up to 41.285 μM. I and II as inhibitors of factor Xa should prove useful in the treatment of. Pharmaceutical compns. comprising I and II are disclosed.


IT 863483-71-0P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrrole derivs. as factor Xa inhibitors)

RN 863483-71-0 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl]-4-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, phenylmethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 863483-70-9
 CIP C28 H32 Cl N5 O4

PAGE 1-A



L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



CH 2

CRN 76-05-1
 CIP C2 H F3 O2




IT 863483-70-9P 863483-76-5P 863483-77-6P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrrole derivs. as factor Xa inhibitors)

RN 863483-70-9 CAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl]-4-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 863483-76-5 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl]-4-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


1/27/06

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 863483-77-6 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl]-4-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, methyl ester, trifluoroacetate (9C1) (CA INDEX NAME)
CH 1
CRN 863483-76-5
CMF C22 H28 Cl N5 O4

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CH 2
CRN 76-05-1
CMF C2 H F3 O2




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:857399 CAPLUS
DOCUMENT NUMBER: 141:343478
TITLE: Use of small molecule compounds for immunopotentialization
INVENTOR(S): Valiante, Nicholas
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087153	A2	20041014	WO 2004-US10331	20040329
WO 2004087153	A3	20050317		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2520124	AA	20041014	CA 2004-2520124	20040329
US 2005136065	A1	20050623	US 2004-814480	20040329
EP 1608369	A2	20051228	EP 2004-758593	20040329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.:			US 2003-458888P	P 20030328
			WO 2004-US10331	W 20040329
OTHER SOURCE(S):			MARPAT 141:343478	
GI				

Same Assignee



AB The invention provides immunostimulatory compns. comprising a small mol. immunopotentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further

~~10034462~~

1/27/06

L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
provided are compns. and methods of administering SMIP compds. alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. Prepn. of selected compds., e.g. 1, is included.


IT 667448-03-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small mol. compds. for immunopotentialization)

RN 667448-03-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 667448-83-1P 667452-44-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(small mol. compds. for immunopotentialization)

RN 667448-83-1 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667452-44-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 667447-52-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(small mol. compds. for immunopotentialization)

RN 667447-52-1 CAPLUS

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:255586 CAPLUS

DOCUMENT NUMBER: 141:38465

TITLE: Synthesis and preliminary antimicrobial evaluation of new 7-(N-pyrrolyl) derivatives of cephalosporins
AUTHOR(S): Bijev, Atanas; Nankov, Atanas; Keuleyan, Emma; Markovska, Rumiana; Daneva, Elitsa
CORPORATE SOURCE: University of Chemical Technology and Metallurgy, Sofia, Bulg.

SOURCE: Arzneimittel Forschung (2004), 54(2), 119-124

CODEN: ARZNAD; ISSN: 0004-4172

Edicio Cantor Verlag

JOURNAL: English

OTHER SOURCE(S): CASREACT 141:38465

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A series of seven new cephalosporins I [X = (CH₂)_n, R = EtO, R₁ = H, Ph, n = 1; R = EtO, R₁ = H, Me, Cl, Ph, n = 2; R = R₁ = Me, n = 2] was prepared for preliminary microbiol. evaluation by N-acylation of 7-aminocephalosporanic acid with substituted N-pyrrolylcarboxylic acids II via mixed anhydrides. The chemical structure of the compds. were confirmed by IR, ¹H-NMR and mass spectral data. The 7-(N-pyrrolyl) cephalosporin derivs. were tested in vitro by the disk diffusion method upon 3 strains and subsequent determination of the minimal inhibitory concentration (MIC)

of the most active ones upon 29 strains. The products of the series exhibited antibacterial activity. They showed selective potency against Gram-pos. and were practically inactive against Gram-neg. microorganisms. The compound 3-[(acetyloxy)methyl]-7-[(2-[3-(ethoxycarbonyl)-2-methyl-5-phenyl-1H-1-pyrrolyl]acetyl)amino]-6-oxo-7,7a-dihydro-2H,6H-aceto[2,1-b][1,3]thiazine-4-carboxylic acid I (R = EtO, R₁ = H, n = 1) (III) was outlined as more active than the reference cefazolin (CAS 23325-78-2) in regard

to S. pyogenes and some strains of S. aureus, the MIC of III against S. pyogenes were at least 4-fold lower. The toxicol. evaluations of the starting N-pyrrolylcarboxylic acids showed no acute toxicity.

IT 701254-02-6P 701254-16-2P 701254-18-4P

701254-20-8P 701254-22-0P 701254-24-2P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antibacterial activity of 7-(N-pyrrolyl) cephalosporin derivs.)


RN 701254-02-6 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[[3-(ethoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrolyl]acetyl]amino]-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

1/27/06

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




```

RN 701254-16-2 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-( (acetoxy)methyl)-7-[[[5-(1,1'-biphenyl)-4-yl]-3-(ethoxycarbonyl)-2-
methyl-1H-pyrrol-1-yl]acetyl]amino]-8-oxo-, (6R,7R)-(9CI) (CA INDEX
NAME)

```


Absolute stereochemistry.



RN 701254-18-4 CAPLUS
 CN 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(acetyloxy)methyl]-7-[[3-[3-(ethoxycarbonyl)-2-methyl-5-phenyl-1H-
 pyrrrol-1-yl]-1-oxopropyl]amino]-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 701254-20-8 CAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(acetyloxy)methyl]-7-[[3-[3-(ethoxycarbonyl)-2-methyl-5-(4-
 methylphenyl)-1H-pyrrol-1-yl]-1-oxopropyl]amino]-8-oxo-, (6R,7R)- (9C)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 701254-22-0 CAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-(1-(acetyloxy)methyl)-7-[(3-[5-(4-chlorophenyl)-3-(ethoxycarbonyl)-2-
 methyl-1H-pyrrol-1-yl]-1-oxopropyl)amino]-8-oxo-, (6R, 7R)- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 701254-24-2 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(acetyloxy)methyl]-7-[[3-[5-[1,1'-biphenyl]-4-yl]-3-(ethoxycarbonyl)-2-
methyl-1H-pyrrol-1-yl]-1-oxopropyl]amino]-6-oxo-, (6R,7R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 199404182869 CAPLUS 2800 ACS ON SYN
DOCUMENT NUMBER: 104:235595
TITLE: Preparation of pyrrole based selective inhibitors of
glycogen synthase kinase 3 for treating diabetes and
other disorders
INVENTOR(S): Desai, Manoj; Ni, Zhi-Jie; Ng, Simon; Pfister, Keith
B.; Ramurthy, Savithri; Subramanian, Sharadha; Wagman,
Allen S.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 110 pp. \n
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018455	A1	20040304	WO 2003-026625	20030821
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FG, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, BG, GR, HU, IE, IT, LU, MC, ML, PT, RO, SE, SI, SK, TR, BF, BJ, BR, CF, CG, CI, CM, CA, GN, GQ, MG, ML, MR, NE, SN, TD, TG			
US 2496246	AA	20040304	CA 2003-2496246	20030821
US 2004077007	A1	20040402	US 2002-036525	20030821
EP 1537099	A1	20050508	EP 2003-749133	20030821
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, ES, MC, PT, IE, SI, BG, LV, FI, RO, MK, CY, AL, TR, BG, CA, SE, HU, SK			
JP 200501243	T2	20060112	JP 2004-531200	20030821
PRIORITY APPLN. INFO.:			US 2002-045846P-	P 20020823
			WO 2003-026625-	W 20030821
OTHER SOURCE(S):	HARPAT 140:235595			
GI				

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




II

AB New pyrrole based compds. (shown as I; variables defined below; e.g. II), compns. and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compds. and compns. of the invention may be employed alone, or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer. For I: X is N, O, or (un)substituted C; V is absent or -O-, -S-, -S(O)-, -SO₂-, -NH-, -NH-CO-, -NH⁺-CO-, -NH⁺SO₂-, -NR⁺SO₂-, -CO-, -CO₂-, -CH₂-, -CF₂-, -CH₂F-, -CONH-, -CONR⁺-, and -NR⁺-, where R⁺ is (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo; A1 is (un)substituted aryl or heteroaryl; R0 and R0⁺ = H and Me. R1, R2, R3, and R4 = H, hydroxy, and (un)substituted loweralkyl, cycloloweralkyl, cyclicaminoalkyl, alkylaminoalkyl, loweralkoxy, amino, alkylamino, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, aryl and heteroaryl. R5 and R8 = H, halo, and (un)substituted loweralkyl, cycloalkyl, alkoxy, amino, aminoalkoxy, carbonyloxy, aminocarbonyloxy, alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cycloimido, heterocycloimido, amidino, cycloamidino, heterocycloamidino, guanidiny, aryl, biaryl, heteroaryl, heteroarylaryl, heteroarylheteroaryl, heterocycloalkyl, heterocycloalkylalkoxy, heteroarylcarbonyloxy, and arylsulfonamido. R6 = H, and (un)substituted aryl, heteroaryl, and heterocyclo; R7 = H, hydroxy, halo, carboxy, nitro, amino, amido, amidino, imido, cyano, sulfonyl, methanesulfonyl, and (un)substituted alkyl, alkoxy, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy,

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 aralkylcarbonyloxy, ester; addnl. details are given in the claim.
 Although the methods of prepn. are not claimed, example prepn. and characterization data are included for hundreds of I. For example, II was prepd. in 7 steps starting with esterification of (E)-3-(2,4-dichlorophenyl)-2-propenoic acid with tBuOH, followed by cyclization with p-tolylSO₂CH₂NC to give 4-(2,4-dichlorophenyl)pyrrole-3-carboxylic acid tert-Bu ester, followed by N-alkylation with 3-bromopropylphthalimide, followed by conversion of the phthalimide to the diamine with hydrazine, followed by N-substitution with (6-chloro-3-nitro-2-pyridyl)amine to give 1-[3-[(6-amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)pyrrole-3-carboxylic acid tert-Bu ester, followed by acid hydrolysis and carboxamide formation with (2S)-(+)-2-aminopropan-1-ol to give II. Representative I have GSK3 inhibitory activity <10 μM (specific compds. not mentioned); they exhibit a selectivity of 22-fold for GSK3 as compared to another kinase and more typically they exhibit a selectivity of 25-fold. Compds. I were shown to be capable of significantly reducing the potential of glutamate to induce neuronal cell death. In the glucose tolerance test, representative I exhibited good in vitro potency, and when formulated in capitolol and administered s.c. to mice (30 mg/kg), exhibited high bioavailability and tissue penetration in vivo. A significant redn. in basal hyperglycemia just prior to the glucose tolerance test, and significantly improved glucose disposal following glucose challenge were obsd., comparable to the efficacy obtained with Troglitazone. Also of significance was the observation that insulin levels in treated animals remained lower than in control mice.
 IT 667452-44-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)pyrrole-3-carboxylic acid tert-butyl ester
 R1: PAC (Pharmacological activity); RCT (Reactant); SPV (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Drug candidate; preparation of pyrrole-based selective inhibitors of glycogen synthase kinase 3 for treating diabetes and other disorders)
 RW 667452-44-0 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-, 1,1-dimethylethyl ester (9C1) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



IT 667447-37-2P, N-[(1S)-2-Hydroxyisopropyl]-1-[3-[(6-amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)pyrrole-3-carboxamide 667447-38-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-(2-cyanoethyl)-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrole-3-carboxamide 667447-39-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-(2-hydroxyethyl)-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrole-3-carboxamide 667447-40-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrole-3-carboxamide 667447-41-0P, N-[(1S)-1-Carbanoyl-2-hydroxyethyl]-1-[3-[(6-amino-5-nitropyridin-2-yl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]pyrrole-3-carboxamide 667447-42-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-cyclopropyl-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrole-3-carboxamide 667447-43-0P, Methyl N-[1-[3-[(6-amino-5-nitropyridin-2-yl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrol-3-yl]carbonyl]serinate 667447-44-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-pyrrole-3-carboxamide 667447-45-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-[(2S)-2-hydroxypropyl]-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrole-3-carboxamide 667447-46-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrole-3-carboxamide 667447-47-4P, 1-[3-[(5-Cyanopyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-48-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(2-hydroxy-1-hydroxymethyl)ethyl]-1H-pyrrole-3-carboxamide 667447-49-6P, N-[2-(Acetylaminomethyl)-1-[3-[(6-amino-5-nitropyridin-2-yl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrole-3-carboxamide 667447-50-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-51-0P, 1-[3-[(5-Cyanopyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide 667447-52-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide 667447-53-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-54-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide 667447-55-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide 667447-56-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1-[3-[(5-nitropyridin-2-yl)amino]propyl]-1H-pyrrole-3-carboxamide 667447-57-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-N-[2-(pyridin-2-yl)ethyl]-1H-pyrrole-3-carboxamide 667447-58-7P, 4-(2,4-Dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1-[3-[(5-nitropyridin-2-yl)amino]propyl]-1H-pyrrole-3-carboxamide 667447-59-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrole-3-carboxamide 667447-60-1P, 4-(2,4-Dichlorophenyl)-N-[(2S)-2-hydroxypropyl]-1-[3-[(5-nitropyridin-2-yl)amino]propyl]-1H-pyrrole-3-carboxamide 667447-61-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide 667447-62-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide 667447-63-4P, 4-(2,4-Dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]-1-[3-[(5-nitropyridin-2-yl)amino]propyl]-1H-pyrrole-3-carboxamide 667447-64-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-65-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-66-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-67-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide 667447-68-9P, 4-(2,4-Dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1-[3-[(5-nitropyridin-2-yl)amino]propyl]-1H-pyrrole-3-carboxamide 667447-69-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-70-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(4-hydroxycyclohexyl)-1H-pyrrole-3-carboxamide 667447-71-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-72-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-73-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-74-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-75-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-76-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-77-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-78-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-79-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-80-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-81-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-82-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-83-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-84-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-85-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-86-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-87-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-88-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-89-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-90-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-91-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-92-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-93-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-94-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-95-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-96-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-97-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-98-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-99-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-00-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-01-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-02-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-03-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-04-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-05-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-06-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-07-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-08-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-09-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-10-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-11-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-12-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-13-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-14-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-15-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-16-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-17-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-18-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-19-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-20-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-21-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-22-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-23-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-24-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-25-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-26-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-27-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-28-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-29-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-30-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-31-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-32-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-33-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-34-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-35-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-36-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-37-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-38-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-39-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-40-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-41-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-42-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-43-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-44-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-45-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-46-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-47-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-48-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-49-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-50-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-51-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-52-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-53-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-54-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-55-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-56-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-57-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-58-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-59-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-60-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-61-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-62-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-63-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-64-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-65-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-66-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-67-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-68-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447-69-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide 667447

14 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[2-(2-methyl-4-nitro-2,3-dihydro-1H-imidazol-1-yl)ethyl]-1H-pyrrole-3-
carboxamide 667447-66-1P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(2-hydroxy-1,1-dimethylethyl)-1H-
pyrrole-3-carboxamide 667447-86-3P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-(morpholin-4-
yl)ethyl]-1H-pyrrole-3-carboxamide 667447-89-4P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[3-(2-oxopyrrolidin-1-yl)propyl]-1H-pyrrole-3-carboxamide
667447-91-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
[2,4-dichlorophenyl]-N-(3-hydroxypropyl)-1H-pyrrole-3-carboxamide
667447-92-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-(2-pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
667447-94-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2-chlorophenyl)-N-(2R)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide
667447-95-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-(2-hydroxy-3-(morpholin-4-yl)propyl)-1H-pyrrole-3-
carboxamide 667447-96-3P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(2-hydroxy-3-(pyrrolidin-1-
yl)propyl)-1H-pyrrole-3-carboxamide 667447-97-4P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-ethylphenyl)-N-((1R)-
2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide 667447-99-6P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[2-(pyridin-3-yl)ethyl]-1H-pyrrole-3-carboxamide 667448-00-2P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[(2S)-tetrahydrofuran-2-yl)methyl]-1H-pyrrole-3-carboxamide
667448-03-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2-chlorophenyl)-N-((2S)-2-hydroxypropyl)-1H-pyrrole-3-carboxamide
667448-04-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-[3-(morpholin-4-yl)propyl]-1H-pyrrole-3-carboxamide
667448-05-7P, N-(3-Aminocyclohexyl)-1-[3-[(6-Amino-5-nitropyridin-
2-yl)amino]propyl]-4-(4-(1H-imidazol-1-yl)phenyl)-1H-pyrrole-3-carboxamide
667448-06-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-[3-(dimethylamino)-2,2-dimethylpropyl]-1H-pyrrole-3-
carboxamide 667448-07-9P, N-(2-Aminoethyl)-1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-pyrrole-3-
carboxamide 667448-08-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
[2-[(5-cyanopyridin-2-yl)amino]ethyl]-4-(4-(1H-imidazol-
1-yl)phenyl)-1H-pyrrole-3-carboxamide 667448-09-1P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[(pyridin-2-yl)methyl]-1H-pyrrole-3-carboxamide 667448-10-4P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[2-(pyridin-2-yl)ethyl]-1H-pyrrole-3-carboxamide 667448-11-5P,
4-(2,4-Dichlorophenyl)-1-[3-[(5-nitropyridin-2-yl)amino]propyl]-1H-pyrrole-3-
carboxylic acid tert-butyl ester 667448-12-6P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[2-(pyridin-4-yl)ethyl]-1H-pyrrole-3-carboxamide 667448-13-7P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-chloro-4-
fluorophenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester
667448-14-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-[(2R)-tetrahydrofuran-2-yl)methyl]-1H-pyrrole-3-
carboxamide 667448-18-2P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[3-(4-methylpiperazin-1-
yl)propyl]-1H-pyrrole-3-carboxamide 667448-21-7P,
1-[3-[(5-cyanopyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-pyrrole-

14 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
pyrrole-3-carboxamide 667448-61-5P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(4-ethylphenyl)-N-((1S)-2-hydroxy-1-
methylethyl)-1H-pyrrole-3-carboxamide 667448-63-7P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
ethyl-N-[(pyridin-4-yl)methyl]-1H-pyrrole-3-carboxamide
667448-65-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-difluorophenyl)-N-((2R)-2-hydroxypropyl)-1H-pyrrole-3-carboxamide
667448-66-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-(2-methoxyethyl)-1H-pyrrole-3-carboxamide
667448-67-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
[(1S)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide
667448-69-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-
pyrrole-3-carboxylic acid (1-aminocyclopentyl)methyl ester
667448-70-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
[(3R,4R)-1-azabicyclo[2.2.1]hept-3-yl]-4-(2,4-dichlorophenyl)-1H-pyrrole-3-
carboxamide 667448-73-9P, 4-(2,4-Dichlorophenyl)-N-((1R)-2-
hydroxy-1-methylethyl)-1-[3-[(5-(trifluoromethyl)pyridin-2-
yl)amino]propyl]-1H-pyrrole-3-carboxamide 667448-76-2P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-difluorophenyl)-N-
(1R)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide
667448-81-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2-chlorophenyl)-1H-pyrrole-3-carboxylic acid 667448-83-1P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-
pyrrole-3-carboxylic acid 667448-84-2P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(piperidin-4-
yl)methyl]-1H-pyrrole-3-carboxamide 667448-87-5P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-difluorophenyl)-N-
(1S)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide
667448-88-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(4-chloro-2-fluorophenyl)-N-((1S)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-
carboxamide 667448-89-7P, 4-(2,4-Dichlorophenyl)-1-[3-[(5-
nitropyridin-2-yl)amino]propyl]-1H-pyrrole-3-carboxylic acid
667448-90-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
(1R)-2-hydroxy-1-methylethyl)-4-(4-methylphenyl)-1H-pyrrole-3-carboxamide
667448-93-3P, 4-(2,4-Dichlorophenyl)-N-((1S)-2-hydroxy-1-
methylethyl)-1-[3-[(5-(trifluoromethyl)pyridin-2-yl)amino]propyl]-1H-
pyrrole-3-carboxamide 667448-94-4P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(4-cyanophenyl)-N-((2R)-2-hydroxypropyl)-
1H-pyrrole-3-carboxamide 667448-95-5P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(4-cyanophenyl)-N-((1S)-2-hydroxy-1-
methylethyl)-1H-pyrrole-3-carboxamide 667448-96-6P, tert-Butyl
[2-[[1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-
dichlorophenyl)-1H-pyrrole-3-yl]carboxyl]methyl]-1H-imidazol-4-
yl)methyl)-1H-pyrrole-3-carboxamide 667448-97-7P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(4-(trifluoromethoxy)phenyl)-1H-pyrrole-3-
carboxamide 667448-98-8P, 4-(2,4-Dichlorophenyl)-N-((2R)-2-
hydroxypropyl)-1-[3-[(5-(trifluoromethyl)pyridin-2-yl)amino]propyl]-1H-
pyrrole-3-carboxamide 667449-00-5P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-fluorophenyl)-N-((2S)-2-
hydroxypropyl)-1H-pyrrole-3-carboxamide 667449-02-7P,
N-[(1S)-2-hydroxy-1-methylethyl]-1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-
dichlorophenyl)-1H-pyrrole-3-carboxamide 667449-03-8P, 4-(2,4-Dichlorophenyl)-N-((2S)-2-hydroxypropyl)-1-[3-
[(5-(trifluoromethyl)pyridin-2-yl)amino]propyl]-1H-pyrrole-3-carboxamide
667449-04-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
[(1H-benzimidazol-2-yl)methyl]-4-(2,4-dichlorophenyl)-1H-pyrrole-3-
carboxamide 667449-05-0P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(4-bromo-2-fluorophenyl)-N-((2R)-2-hydroxypropyl)-1H-

14 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
3-carboxylic acid tert-butyl ester 667448-22-8P, tert-Butyl
N-[(1S)-2-hydroxy-1-methylethyl]-1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-
dichlorophenyl)-1H-pyrrole-3-carboxamide 667448-23-9P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-((2S)-2-hydroxypropyl)-1H-
pyrrole-3-carboxamide 667448-24-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(4-(1H-imidazol-1-yl)phenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester
667448-28-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2-chloro-4-fluorophenyl)-1H-pyrrole-3-carboxylic acid
667448-29-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-[(1-hydroxy-2-methylcyclopentyl)-1H-pyrrole-3-
carboxamide 667448-30-6P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2-(1-methylpyrrolidin-2-
yl)ethyl)-1H-pyrrole-3-carboxamide 667448-31-9P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-[(3R)-1-
azabicyclo[2.2.2]oct-3-yl]-4-(4-(1H-imidazol-1-yl)phenyl)-1H-pyrrole-3-
carboxamide 667448-32-0P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2-(piperidin-1-yl)ethyl)-1H-
pyrrole-3-carboxamide 667448-33-1P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(2-chlorophenyl)-1H-pyrrole-3-carboxylic
acid tert-butyl ester 667448-35-3P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(4-ethylphenyl)-N-((2S)-2-hydroxypropyl)-
1H-pyrrole-3-carboxamide 667448-37-5P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2-
dimethylamino)ethyl]-1H-pyrrole-3-carboxamide 667448-38-6P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[(pyridin-3-yl)methyl]-1H-pyrrole-3-carboxamide 667448-39-7P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-
pyrrole-3-carboxylic acid 2-amino-2-methylpropyl ester
667448-40-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-[3-(1H-imidazol-1-yl)propyl]-1H-pyrrole-3-
carboxamide 667448-41-1P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(5-methylpyrazin-2-yl)methyl]-
1H-pyrrole-3-carboxamide 667448-45-5P, N-[(1S)-2-hydroxy-1-
nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-pyrrole-3-
yl]carboxyl]serine 667448-46-6P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-4-(4-(1H-imidazol-1-
yl)phenyl)-1H-pyrrole-3-carboxamide 667448-47-7P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-cyanophenyl)-N-((1R)-
2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide 667448-48-8P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[3-(2-methylpiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide
667448-50-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-[(2-furyl)methyl]-1H-pyrrole-3-carboxamide
667448-51-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(4-chloro-2-fluorophenyl)-N-((1R)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-
carboxamide 667448-54-6P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(4-chlorophenyl)-N-[(2S)-2-hydroxypropyl]-1H-
pyrrole-3-carboxamide 667448-55-7P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-bromo-2-
fluorophenyl)-N-((1R)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide
667448-56-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(4-ethylphenyl)-N-((2R)-2-hydroxypropyl)-1H-pyrrole-3-carboxamide
667448-59-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-[(pyridin-4-yl)methyl]-1H-pyrrole-3-carboxamide
667448-60-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(4-chloro-2-methoxyphenyl)-N-[(2-[(2-cyanophenyl)sulfonyl]amino]ethyl)-1H-


14 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
pyrrole-3-carboxamide 667448-06-1P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(2,4-difluorophenyl)-N-((2S)-2-
hydroxypropyl)-1H-pyrrole-3-carboxamide 667449-07-2P,
1-[3-[(5-Cyanopyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-pyrrole-3-
carboxylic acid 667449-08-3P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(4-cyanophenyl)-N-((2S)-2-hydroxypropyl)-1H-pyrrole-3-
carboxamide 667449-09-4P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(4-bromo-2-fluorophenyl)-N-((2S)-2-hydroxypropyl)-1H-
pyrrole-3-carboxamide 667449-10-7P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-N-[(3S,4S)-1-azabicyclo[2.2.1]hept-3-yl]-4-
(2,4-dichlorophenyl)-1H-pyrrole-3-carboxamide 667449-11-8P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-bromo-2-
fluorophenyl)-N-((1S)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide
667449-14-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(4-ethylphenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester
667449-15-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
(2S)-2-hydroxypropyl)-4-(4-(trifluoromethoxy)phenyl)-1H-pyrrole-3-
carboxamide 667449-16-3P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(4-chloro-2-fluorophenyl)-N-((2R)-2-hydroxypropyl)-1H-
pyrrole-3-carboxamide 667449-21-0P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(4-bromophenyl)-N-((1R)-2-hydroxy-1-
methylethyl)-1H-pyrrole-3-carboxamide 667449-23-2P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chlorophenyl)-N-((1R)-2-
hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide 667449-25-4P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chlorophenyl)-N-
(2S)-2-hydroxypropyl)-1H-pyrrole-3-carboxamide 667449-26-5P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-((1R)-2-hydroxy-1-
methylethyl)-4-(4-methoxyphenyl)-1H-pyrrole-3-carboxamide
667449-27-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(4-fluorophenyl)-N-((1R)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide
667449-28-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
(2R)-2-hydroxypropyl)-4-(4-(trifluoromethoxy)phenyl)-1H-pyrrole-3-
carboxamide 667449-29-8P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(4-cyanophenyl)-1H-pyrrole-3-carboxylic acid tert-butyl
ester 667449-31-2P, 1-[3-[(6-Amino-5-nitropyridin-2-
yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2-phenyl-1H-imidazol-4-
yl)methyl]-1H-pyrrole-3-carboxamide 667449-32-3P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
[(quinolin-2-yl)methyl]-1H-pyrrole-3-carboxamide 667449-34-5P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-fluorophenyl)-N-
(2R)-2-hydroxypropyl)-1H-pyrrole-3-carboxamide 667449-35-6P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-cyanophenyl)-1H-
pyrrole-3-carboxylic acid 667449-37-8P, 1-[3-[(6-Amino-5-
nitropyridin-2-yl)amino]propyl]-4-(4-fluorophenyl)-N-((2S)-2-
hydroxypropyl)-1H-pyrrole-3-carboxamide 667449-38-9P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-benzyl-4-(2,4-
dichlorophenyl)-1H-pyrrole-3-carboxamide 667449-40-3P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-((2S)-2-hydroxypropyl)-
4-(4-methylphenyl)-1H-pyrrole-3-carboxamide 667449-44-7P,
1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-((1S)-2-hydroxy-1-
methylethyl)-4-(4-(trifluoromethoxy)phenyl)-1H-pyrrole-3-carboxamide
667449-46-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(4-fluorophenyl)-N-((1S)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide
667449-47-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(2,4-dichlorophenyl)-N-[(2-(1H-indol-3-yl)ethyl)-1H-pyrrole-3-carboxamide
667449-48-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
(2S)-2-hydroxypropyl)-4-(4-methoxyphenyl)-1H-pyrrole-3-carboxamide
667449-54-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
(3-chlorophenyl)-N-((1R)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 667449-58-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
 ((1S)-2-hydroxy-1-methylethyl)-4-(4-methylphenyl)-1H-pyrrole-3-carboxamide
 667449-62-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
 ((2R)-2-hydroxypropyl)-4-(4-methoxyphenyl)-1H-pyrrole-3-carboxamide
 667449-72-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
 ((2R)-2-hydroxypropyl)-4-(4-methylphenyl)-1H-pyrrole-3-carboxamide
 667449-74-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
 (4-chloro-2-fluorophenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester
 667449-78-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
 (4-bromo-2-fluorophenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester
 667449-82-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
 (1-benzylpiperidin-4-yl)-4-(2,4-dichlorophenyl)-1H-pyrrole-3-carboxamide
 667449-84-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
 ((1S)-2-hydroxy-1-methylethyl)-4-(4-methoxyphenyl)-1H-pyrrole-3-
 carboxamide 667449-88-9P, 1-[3-[(6-Amino-5-nitropyridin-2-
 yl)amino]propyl]-N-((1S)-1-benzyl-2-hydroxyethyl)-4-(2,4-dichlorophenyl)-
 1H-pyrrole-3-carboxamide 667449-92-5P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(2,4-difluorophenyl)-1H-pyrrole-3-
 carboxylic acid tert-butyl ester 667449-94-7P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-
 ((5-methyl-3-phenylisoxazol-4-yl)methyl)-1H-pyrrole-3-carboxamide
 667450-00-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
 (4-bromophenyl)-N-((2R)-2-hydroxypropyl)-1H-pyrrole-3-carboxamide
 667450-02-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
 (4-bromophenyl)-N-((2S)-2-hydroxypropyl)-1H-pyrrole-3-carboxamide
 667450-04-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
 ((1R)-2-hydroxy-1-methylethyl)-4-(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-
 carboxamide 667450-06-9P, 1-[3-[(6-Amino-5-nitropyridin-2-
 yl)amino]propyl]-4-(4-chlorophenyl)-N-((2R)-2-hydroxypropyl)-1H-pyrrole-3-
 carboxamide 667450-10-4P, 4-(2,4-Dichlorophenyl)-1-[3-[(5-
 (trifluoromethyl)pyridin-2-yl)amino]propyl]-1H-pyrrole-3-carboxylic acid
 tert-butyl ester 667450-12-6P, 1-[3-[(6-Amino-5-nitropyridin-2-
 yl)amino]propyl]-4-(4-chlorophenyl)-N-((1S)-2-hydroxy-1-methylethyl)-1H-
 pyrrole-3-carboxamide 667450-16-0P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(4-methylphenyl)-1H-pyrrole-3-carboxylic
 acid tert-butyl ester 667450-18-2P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(4-bromophenyl)-N-((1S)-2-hydroxy-1-
 methylethyl)-1H-pyrrole-3-carboxamide 667450-20-4P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(3-chlorophenyl)-N-
 ((2S)-2-hydroxypropyl)-1H-pyrrole-3-carboxamide 667450-28-4P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(4-methoxyphenyl)-1H-
 pyrrole-3-carboxylic acid tert-butyl ester 667450-30-8P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-N-((2R)-2-hydroxypropyl)-
 4-(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide
 667450-34-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
 (3-chlorophenyl)-N-((2R)-2-hydroxypropyl)-1H-pyrrole-3-carboxamide
 667450-48-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
 (3-chlorophenyl)-N-((1S)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-carboxamide
 667450-52-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-N-
 ((2S)-2-hydroxypropyl)-4-(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-
 carboxamide 667450-54-6P, 1-[3-[(6-Amino-5-nitropyridin-2-
 yl)amino]propyl]-4-(2,4-difluorophenyl)-1H-pyrrole-3-carboxylic acid
 667450-56-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-
 (4-fluorophenyl)-1H-pyrrole-3-carboxylic acid 667450-58-0P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(4-ethylphenyl)-1H-

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 pyrrole-3-carboxylic acid 667450-64-8P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-(2-
 hydroxyethyl)-1H-pyrrole-3-carboxamide 667450-68-2P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(4-methoxyphenyl)-1H-
 pyrrole-3-carboxylic acid 667450-70-6P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-N-((1S)-2-hydroxy-1-methylethyl)-4-(4-
 (trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide 667450-74-0P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(2-fluoro-4-
 (trifluoromethyl)phenyl)-N-((1R)-2-hydroxy-1-methylethyl)-1H-pyrrole-3-
 carboxamide 667450-76-2P, 1-[3-[(6-Amino-5-nitropyridin-2-
 yl)amino]propyl]-4-(2,4-dichlorophenyl)-N-4-(diethylamino)benzyl)-1H-
 pyrrole-3-carboxamide 667450-84-2P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(4-(trifluoromethoxy)phenyl)-1H-pyrrole-
 3-carboxylic acid tert-butyl ester 667450-94-4P, 1-[3-[(6-Amino-5-nitropyridin-2-
 yl)amino]propyl]-4-(4-bromophenyl)-1H-
 pyrrole-3-carboxylic acid tert-butyl ester 667450-98-8P, 1-[3-[(6-Amino-5-
 nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-
 fluorophenyl)-1H-pyrrole-3-carboxylic acid
 RN: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BICL (Biological study); PREP (Preparation); USES
 (Uses)


(drug candidate; prepn. of pyrrole-based selective inhibitors of
 glycogen synthase kinase 3 for treating diabetes and other disorders)
 RN 667447-37-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-
 4-(2,4-dichlorophenyl)-N-((1S)-2-hydroxy-1-methylethyl)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 667447-38-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-
 N-(2-cyanoethyl)-4-(4-(1H-imidazol-1-yl)phenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PAGE 1-A



PAGE 2-A

RN 667447-39-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-
 N-(2-hydroxyethyl)-4-(4-(1H-imidazol-1-yl)phenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PAGE 1-A




PAGE 2-A

RN 667447-40-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-
 4-(4-(1H-imidazol-1-yl)phenyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 667447-41-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[(1S)-2-amino-1-(hydroxymethyl)-2-oxoethyl]-1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-A



L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667447-42-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-cyclopropyl-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 667447-43-0 CAPLUS
CN L-Serine, N-[[1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrol-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667447-44-1 CAPLUS

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 667447-45-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2S)-2-hydroxypropyl]-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667447-46-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667447-47-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(5-cyano-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667447-48-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)

10691423


1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667447-49-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetamino)ethyl]-1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667447-52-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667447-53-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 667447-50-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667447-51-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(5-cyano-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667447-54-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(5-cyano-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667447-55-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-[(1H-imidazol-1-yl)phenyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 667447-56-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-[(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1-[3-[(5-nitro-2-pyridinyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A


RN 667447-58-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667447-59-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(5-cyano-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667447-60-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]-1-[3-[(5-nitro-2-pyridinyl)amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667447-57-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667447-62-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667447-63-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]-1-[3-[(5-nitro-2-pyridinyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


~~1-6681-423~~

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667447-64-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 667447-66-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2-hydroxyethoxy)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667447-70-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667447-67-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667447-69-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1-[3-[(5-nitro-2-pyridinyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 667447-71-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667447-72-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


~~10631423~~

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667447-73-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)




RN 667447-74-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 667447-77-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



Page 16


saeed

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667447-75-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667447-76-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 667447-79-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 667447-80-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667447-81-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)




RN 667447-83-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A

RN 667447-85-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)




RN 667447-86-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)




RN 667447-88-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667447-84-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2S)-2-hydroxy-1-methylethyl]-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 667447-89-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667447-91-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 667447-92-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 667447-96-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667447-94-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chlorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667447-95-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-hydroxy-3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667447-97-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-ethylphenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667447-99-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

~~12631123~~

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 667448-00-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667448-03-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 667448-04-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 667448-05-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3-aminocyclohexyl)-1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 667448-06-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


~~10631423~~

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667448-07-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-aminoethyl)-1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 667448-08-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[2-[(5-cyano-2-pyridinyl)amino]ethyl]-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 667448-10-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 667448-09-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A





RN 667448-11-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2,4-dichlorophenyl)-1-[3-[(5-nitro-2-pyridinyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 667448-12-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




RN 667448-18-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



PAGE 2-A




RN 667448-13-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chloro-4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 667448-14-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[[2R]-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 667448-21-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(5-cyano-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 667448-22-8 CAPLUS
CN D-Serine, N-[[1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-pyrrol-3-yl]carbonyl]-O-(1,1-dimethylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667448-24-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10691423

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 667448-28-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)


PAGE 2-A



L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667448-29-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[1-(hydroxymethyl)cyclopentyl]- (9CI) (CA INDEX NAME)




RN 667448-30-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667448-31-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 667448-32-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 667448-33-1 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chlorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10631422


1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667448-35-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-ethylphenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667448-37-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A



RN 667448-39-7 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-, 2-amino-2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 667448-40-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 667448-41-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(5-methylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)

Page 23


saeed

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667448-38-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 667448-45-5 CAPLUS
 CN L-Serine, N-[[1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667448-46-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667448-47-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-cyanophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 667448-50-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 667448-51-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-fluorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667448-48-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 667448-54-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[2-[(5-nitro-2-pyridinyl)amino]ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 667448-55-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromo-2-fluorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667448-56-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-ethylphenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 667448-60-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[2-[(2-cyanophenyl)sulfonyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667448-59-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 667448-61-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-ethylphenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667448-63-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-ethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



10531423

1/27/06


L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 667448-65-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-difluorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 667448-66-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 667448-69-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-, [(1S,3R,4R)-1-azabicyclo[2.2.1]hept-3-yl]-methyl ester (9CI) (CA INDEX NAME)




RN 667448-70-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1S,3R,4R)-1-azabicyclo[2.2.1]hept-3-yl]-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



RN 667448-67-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-pyrrol-3-yl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667448-73-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]-1-[3-[[5-(trifluoromethyl)-2-pyridinyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667448-76-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-difluorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667448-81-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 667448-83-1 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 667448-87-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-difluorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667448-88-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-fluorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667448-84-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667448-89-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2,4-dichlorophenyl)-1-[3-[(5-nitro-2-pyridinyl)amino]propyl]- (9CI) (CA INDEX NAME)




RN 667448-90-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

~~10691433~~


1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667448-93-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1-[3-[[5-(trifluoromethyl)-2-pyridinyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667448-94-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-cyanophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667448-97-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667448-98-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]-1-[3-[[5-(trifluoromethyl)-2-pyridinyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667448-95-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-cyanophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667448-96-6 CAPLUS
CN Carbamic acid, [2-[[[1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-00-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-fluorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667449-02-7 CAPLUS
CN L-Serine, N-[[1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-1H-pyrrol-3-yl]carbonyl]-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

~~1-000-1423~~


1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667449-03-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-[(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]-1-[3-[(5-(trifluoromethyl)-2-pyridinyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667449-04-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-(1H-benzimidazol-2-ylmethyl)-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667449-07-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(5-cyano-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 667449-08-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-cyanophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-05-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromo-2-fluorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667449-06-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-difluorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-09-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromo-2-fluorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667449-10-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-(1R,3S,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

~~10631423~~


1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667449-11-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromo-2-fluorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667449-14-1 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-ethylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 667449-21-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667449-23-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667449-15-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2S)-2-hydroxypropyl]-4-(4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667449-16-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-fluorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-25-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667449-26-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-27-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-fluorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 667449-28-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2R)-2-hydroxypropyl]-4-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667449-32-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 667449-34-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-fluorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667449-35-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-cyanophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667449-29-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-cyanophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 667449-31-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(2-phenyl-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-37-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-fluorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667449-38-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

16631422


1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-40-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2S)-2-hydroxypropyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667449-44-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-48-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2S)-2-hydroxypropyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667449-54-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-46-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667449-47-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2R)-2-hydroxypropyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-58-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667449-62-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2R)-2-hydroxypropyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

~~1-0631423~~


1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-72-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2R)-2-hydroxypropyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 667449-74-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 667449-84-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667449-78-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromo-2-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 667449-82-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-4-(4-bromo-2-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667449-88-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667449-92-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-difluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


~~10631423~~

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667449-94-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[(5-methyl-3-phenyl-4-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)



RN 667450-00-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667450-02-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667450-04-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667450-06-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chlorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667450-10-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2,4-dichlorophenyl)-1-[3-[(5-(trifluoromethyl)-2-pyridinyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667450-12-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667450-16-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667450-18-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667450-20-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(3-chlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667450-34-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(3-chlorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 667450-48-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(3-chlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667450-28-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 667450-30-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2R)-2-hydroxypropyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667450-52-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(2S)-2-hydroxypropyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667450-54-6 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)


18631483

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667450-56-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 667450-58-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-ethylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667450-70-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-[(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 667450-74-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[(2-fluoro-4-(trifluoromethyl)phenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667450-64-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 667450-68-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667450-76-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-N-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 667450-84-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(trifluoromethoxy)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 667450-94-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667450-98-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-fluorophenyl)- (9CI) (CA INDEX NAME)



IT 667451-00-5P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chlorophenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester
667451-02-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-(trifluoromethoxy)phenyl)-1H-pyrrole-3-carboxylic acid

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


667451-08-3P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-methylphenyl)-1H-pyrrole-3-carboxylic acid 667451-10-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chlorophenyl)-1H-pyrrole-3-carboxylic acid 667451-14-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-fluoro-4-(trifluoromethyl)phenyl)-N-(2S)-2-hydroxypropyl-1H-pyrrole-3-carboxamide 667451-20-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-fluoro-4-(trifluoromethyl)phenyl)-N-(2R)-2-hydroxypropyl-1H-pyrrole-3-carboxamide 667451-26-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-fluorophenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester 667451-28-7P, 4-(2,4-Dichlorophenyl)-1-[3-[(5-(trifluoromethyl)pyridin-2-yl)amino]propyl]-1H-pyrrole-3-carboxylic acid 667451-36-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-bromophenyl)-1H-pyrrole-3-carboxylic acid 667451-38-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-fluoro-4-(trifluoromethyl)phenyl)-N-(1S)-2-hydroxy-1-methylethyl-1H-pyrrole-3-carboxamide 667451-48-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-bromo-2-fluorophenyl)-1H-pyrrole-3-carboxylic acid 667451-86-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester 667451-88-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-1H-pyrrole-3-carboxylic acid 667451-90-3P, tert-Butyl 2-[[[1-[3-[(6-amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-1H-pyrrol-3-yl]carbonyl]amino]ethyl]carbamate 667451-92-5P, N-(2-Aminothyl)-1-[3-[(6-amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-1H-pyrrole-3-carboxamide 667451-94-7P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[2-[[[1-(4-cyanophenyl)sulfonyl]amino]ethyl]-1H-pyrrole-3-carboxamide 667451-96-9P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-fluoro-4-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester 667451-98-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(3-chlorophenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester 667452-00-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid tert-butyl ester 667452-02-0P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2-fluoro-4-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid 667452-04-2P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(3-chlorophenyl)-1H-pyrrole-3-carboxylic acid 667452-06-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-[4-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid 667452-08-6P, 1-[4-[(6-Amino-5-nitropyridin-2-yl)amino]butyl]-4-(2,4-dichlorophenyl)-N-(1S)-2-hydroxy-1-methylethyl-1H-pyrrole-3-carboxamide 667452-12-2P, 1-[4-[(6-Amino-5-nitropyridin-2-yl)amino]butyl]-4-(2,4-dichlorophenyl)-N-(2R)-2-hydroxypropyl-1H-pyrrole-3-carboxamide 667452-14-4P, 1-[4-[(6-Amino-5-nitropyridin-2-yl)amino]butyl]-4-(2,4-dichlorophenyl)-N-(1R)-2-hydroxy-1-methylethyl-1H-pyrrole-3-carboxamide 667452-16-6P, 1-[4-[(6-Amino-5-nitropyridin-2-yl)amino]butyl]-4-(2,4-dichlorophenyl)-N-(1S)-2-hydroxy-1-methylethyl-1H-pyrrole-3-carboxylic acid tert-butyl ester 667452-18-8P, 1-[4-[(6-Amino-5-nitropyridin-2-yl)amino]butyl]-4-(2,4-dichlorophenyl)-1H-pyrrole-3-carboxylic acid 667452-26-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[2-[(phenylsulfonyl)amino]ethyl]-1H-pyrrole-3-carboxamide 667452-30-4P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[2-[(3-cyanophenyl)sulfonyl]amino]ethyl]-1H-pyrrole-3-carboxamide

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

667452-32-6P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[2-[(methylsulfonyl)amino]ethyl]-1H-pyrrole-3-carboxamide 667452-34-8P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of pyrrole-based selective inhibitors of glycogen synthase kinase 3 for treating diabetes and other disorders)

RN 667451-00-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chlorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 667451-02-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)


10661423

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667451-08-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 667451-10-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 667451-26-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 667451-28-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2,4-dichlorophenyl)-1-[3-[(5-(trifluoromethyl)-2-pyridinyl)amino]propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667451-14-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[2-fluoro-4-(trifluoromethyl)phenyl]-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667451-20-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[2-fluoro-4-(trifluoromethyl)phenyl]-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667451-36-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 667451-38-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[2-fluoro-4-(trifluoromethyl)phenyl]-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667451-48-1 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-bromo-2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 667451-86-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667451-88-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 667451-90-3 CAPLUS
CN Carbamic acid, [2-[[[1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667451-92-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-aminoethyl)-1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 667451-94-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[[[1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[2-[[[4-cyanophenyl]sulfonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




PAGE 1-A




PAGE 2-A

RN 667451-96-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[2-fluoro-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667451-98-1 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(3-chlorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 667452-00-8 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667452-06-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 667452-08-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[4-[(6-amino-5-nitro-2-pyridinyl)amino]butyl]-4-(2,4-dichlorophenyl)-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667452-02-0 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-[2-fluoro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 667452-04-2 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667452-10-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[4-[(6-amino-5-nitro-2-pyridinyl)amino]butyl]-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667452-12-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[4-[(6-amino-5-nitro-2-pyridinyl)amino]butyl]-4-(2,4-dichlorophenyl)-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667452-14-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[4-[(6-amino-5-nitro-2-pyridinyl)amino]butyl]-4-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667452-16-6 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[4-[(6-amino-5-nitro-2-pyridinyl)amino]butyl]-4-(2,4-dichlorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667452-30-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[2-[(3-cyanophenyl)sulfonyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 667452-18-8 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[4-[(6-amino-5-nitro-2-pyridinyl)amino]butyl]-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 667452-26-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[2-[(phenylsulfonyl)amino]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 667452-32-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[2-[(methylsulfonyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 667452-34-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(4-chloro-2-methoxyphenyl)-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10631483


1/27/06

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 667452-45-1P, 1-[3-[(6-Amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)pyrrole-3-carboxylic acid trifluoroacetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrole-based selective inhibitors of glycogen synthase kinase 3 for treating diabetes and other disorders)
 RN 667452-45-1 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(6-amino-5-nitro-2-pyridinyl)amino]propyl]-4-(2,4-dichlorophenyl)-, trifluoroacetate (9CI)
 (CA INDEX NAME)
 CH 1
 CRN 667448-83-1
 CHF C19 H17 C12 N5 O4

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CH 2
 CRN 76-05-1
 CHF C2 H F3 O2




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:888118 CAPLUS
 DOCUMENT NUMBER: 140:339147
 TITLE: Synthesis of new 1H-1-pyrrolylcarboxamides with potential pharmacological activity
 AUTHOR(S): Bijev, A. T.; Prodanova, P. P.; Nankov, A. N.
 CORPORATE SOURCE: Department of Organic Synthesis and Fuels, University of Chemical Technology and Metallurgy, Sofia, 1756, Bulg.
 SOURCE: Bulgarian Chemical Communications (2003), 35(1), 30-36
 CODEN: BCHKC4; ISSN: 0324-1130
 PUBLISHER: Bulgarian Academy of Sciences and the Bulgarian Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:339147
 GI




AB 1H-1-Pyrrolylcarboxamides I [R1 = Me, Ph; R2 = H, Me; R3 = OEt, Me; R4 = NEt2, morpholino, piperidino, 4-benzhydrylpiperazino, 4-phenyl-2-thiazolyl, pyrrolidino] were prepared from the acids via the acyl chlorides. The 4-phenyl-2-thiazolamine needed preliminary activation by N-silylation because of its lower nucleophilicity. I have been characterized and identified by TLC, NMR and IR spectroscopy.
 IT 679797-35-4P 679797-42-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 1H-1-pyrrolylcarboxamides)
 RN 679797-35-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 2-methyl-1-[2-oxo-2-[(4-phenyl-2-thiazolyl)amino]ethyl]-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 679797-42-3 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 2,4-dimethyl-1-[2-oxo-2-[(4-phenyl-2-thiazolyl)amino]ethyl]-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10634103

1/27/06

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:693238 CAPLUS
 DOCUMENT NUMBER: 139:237604
 TITLE: Silver halide color photographic light-sensitive material such as photographic films
 INVENTOR(S): Yoneyama, Hiroyuki; Ikeda, Akira; Soejima, Shin; Takeuchi, Kiyoshi; Matsuda, Naoto
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 354 pp.
 CODEN: EPXIXW

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1341035	A2	20030903	EP 2003-4340	20030228
EP 1341035	A3	20030924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2003322931	A2	20031114	JP 2002-92878	20020328
JP 2003322932	A2	20031114	JP 2002-92912	20020328
JP 2003322934	A2	20031114	JP 2002-95836	20020329
JP 2003322935	A2	20031114	JP 2002-95865	20020329
JP 2003322936	A2	20031114	JP 2002-107130	20020409
JP 2003322937	A2	20031114	JP 2002-111023	20020412
JP 2003322938	A2	20031114	JP 2002-111282	20020412
JP 2003307818	A2	20031031	JP 2002-112176	20020415
JP 2003322939	A2	20031114	JP 2002-170609	20020611
US 2004091825	A1	20040513	US 2003-373653	20030226
US 2003322940	A2	20031114	JP 2003-54828	20030228
US 2004058284	A1	20040325	US 2003-375053	20030228
EP 1524552	A2	20050420	EP 2005-1345	20030228
EP 1524552	A3	20050615		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, HU, SK				
US 200506926	A1	20050331	US 2004-969205	20041021
US 2005123868	A1	20050609	US 2004-969031	20041021

PRIORITY APPLM. INFO.:

OTHER SOURCE(S):
 GI

MARPAT 139:237604


L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The invention relates to a silver halide color photog. light-sensitive material, having at least one each of blue-, green-, and red-sensitive emulsion layers containing yellow, magenta, and cyan couplers, resp., on a support; wherein the blue-sensitive emulsion layer contains at least one coupler of formula I; and wherein the light-sensitive material satisfies expression (a-1) and/or (b-1); wherein, Q forms a 5- to 7-membered ring with the -N = C-N(R1)-; R1 and R2 each are a substituent; m is 0 to 5; and X is a hydrogen atom, or a coupling split-off group; (a-1): $0.5 \leq D_{\max}(UV)/D_{\min}(UV) \leq 1.1$ wherein $D_{\max}(UV)/D_{\min}(UV)$ is the smallest of the value in a wavelength range of 340 to 450 nm; (b-1): $1300 \leq (B-C)/A \leq 20000$ wherein B is yellow D_{\max} , C is yellow D_{\min} ; and A is an amount mol/m² of the coupler of formula I.


IT 465520-89-2P 465520-92-7P
 RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (coupler in blue-sensitive emulsion layer of photog. films)

RN 465520-89-2 CAPLUS
 CN 1H-Pyrrole-3,4-dicarboxylic acid, 1-[2-[(2,4-difluorophenyl)amino]-1-(2-octadecyl-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 465520-92-7 CAPLUS
 CN 1H-Pyrrole-3,4-dicarboxylic acid, 1-[2-[(2-fluorophenyl)amino]-1-(2-octadecyl-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:327487 CAPLUS
 DOCUMENT NUMBER: 140:76972
 TITLE: Synthesis of new 1H-1-pyrrolylcarboxamides by comparative N-acylation
 AUTHOR(S): Bijev, A. T.; Prodanova, P. P.; Nankov, A. N.
 CORPORATE SOURCE: Department of Organic Synthesis and Fuels, University of Chemical Technology and Metallurgy, Sofia, 1756, Bulg.
 SOURCE: Dokladi na Bulgarskata Akademiya na Naukite (2002), 55 (9), 49-54
 CODEN: DBANEH; ISSN: 0861-1459
 PUBLISHER: Bulgarska Akademiya na Naukite
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:76972
 AB Substituted 1H-1-pyrrolylcarboxamides were prepared by acylation of amines with 1H-pyrrole-1-propanoic acid derivs. via the anhydride or acid chloride. The compds. were characterized using NMR and IR.
 IT 640287-46-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and characterization of)
 RN 640287-46-3 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 2-methyl-1-[3-[(5-methyl-4-phenyl-2-thiazolyl)amino]-3-oxopropyl]-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10631423


1/27/06

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:752420 CAPLUS
 DOCUMENT NUMBER: 137:286348
 TITLE: Color photographic light-sensitive material comprising azomethine dye forming coupler
 INVENTOR(S): Takeuchi, Kiyoshi; Uehira, Shigeki; Aoki, Mario; Ogasawara, Jun; Shimada, Yasuhiro; Ichijima, Seiji; Deguchi, Yasuaki; Matsuda, Naoto; Ikeda, Akira; Mikoshiba, Hisashi; Sugai, Masaharu; Katsumata, Taiji
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 273 pp.
 CODEN: EPKXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1246006	A2	20021002	EP 2002-6628	20020325
EP 1246006	A3	20040811		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003173007	A2	20030620	JP 2002-37488	20020214
US 2003073047	A1	20030417	US 2002-106373	20020327
US 6727053	B2	20040427		
CN 1387087	A	20021225	CN 2002-108474	20020329
US 2004122238	A1	20040624	US 2003-679466	20031007
PRIORITY APPLN. INFO.:			JP 2001-97656	A 20010329
			JP 2001-298521	A 20010927
			JP 2001-298660	A 20010927
			JP 2001-299685	A 20010928
			JP 2002-37488	A 20020214

OTHER SOURCE(S): MARPAT 137:286348
 GI

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Disclosed are a dye-forming coupler of general formula I (Q = -C(R11)-C(R12)-SO2-; R11 and R12 bond with each other to form together with the -C=C-moiety, a 5-7-membered ring, or they each represent a hydrogen atom or a substituent; R1, R3, R4 = substituents; m = 0-4; X represents a hydrogen atom or a group that splits off upon a coupling reaction with an oxidized product of a developing agent) with the proviso that the compound of the formula I is excluded from the dye-forming coupler of formula I. Also disclosed is a silver halide photog. light-sensitive material containing the coupler, and an azomethine dye that can be derived from the dye-forming coupler. The present invention provides color photog. light-sensitive materials including photog. paper that exhibit a high color-forming purity, and in addition they are excellent in fastness to humidity and heat.

IT 465520-89-2 465520-92-7
 RL: TEM (Technical or engineered material use); USES (Uses)
 (coupler; photog. paper comprising azomethine dye forming coupler)


RN 465520-89-2 CAPLUS

CN 1H-Pyrrole-3,4-dicarboxylic acid, 1-[2-[(2,4-difluorophenyl)amino]-1-(2-octadecyl-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 465520-92-7 CAPLUS
 CN 1H-Pyrrole-3,4-dicarboxylic acid, 1-[2-[(2-fluorophenyl)amino]-1-(2-octadecyl-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:418372 CAPLUS
 DOCUMENT NUMBER: 138:92902
 TITLE: Design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors
 AUTHOR(S): Di Santo, Roberto; Costi, Roberta; Artico, Marino; Massa, Silvio; Ragno, Rino; Marshall, Garland R.; La Colla, Paolo
 CORPORATE SOURCE: Dipartimento di Studi Farmaceutici, Istituto Pasteur-Fondazione Cenci Bolognietti, Università degli Studi di Roma 'La Sapienza', Roma, I-00185, Italy
 SOURCE: Bioorganic & Medicinal Chemistry (2002), 10(8), 2511-2526
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:92902

AB A series of N-aryl heteroarylisopropanolamines in which an indole or a 3-arylpyrrole moiety was linked to an aryl group through an isopropanolamine linker, were designed and synthesized as potential anti-HIV-1-PR agents. Series was tested for their ability in blocking PR activity. As a rule, indole derivs. of one class exhibited more potency than pyrrole analogs of another class while tert-butylamide substituents increased anti-PR potency. In fact, bis tert-butylamide showed the highest activity with IC50=25 µM. Even if not very potent, a simple class of anti-PR agents, with a facile synthetic pathway was discovered. QSAR studies on isopropanolamines were performed in comparison with diarylbutanols, a new class of non peptidic anti-PR agents, recently discovered by Agouron Pharmaceuticals. QSAR and CoMFA models based on 30 diarylbutanols used as a training set were developed. The obtained models were used to investigate the binding mode of the newly synthesized isopropanolamine derivs. The results of this study suggest that N-aryl heteroarylisopropanolamines bind to the PR active site similarly to the diarylbutanols of Agouron.

IT 483341-21-5P 483341-22-5P 483341-23-7P
 483341-24-8P 483341-25-9P 483341-26-0P
 483341-27-1P 483341-28-2P 483341-30-6P
 483341-31-7P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors)


RN 483341-21-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 1-[2-hydroxy-3-[(2-methylphenyl)amino]propyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)


~~1/26/06~~
~~2/26/06~~

1/27/06

L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 483341-22-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[2-hydroxy-3-[(3-methylphenyl)amino]propyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 483341-23-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[2-hydroxy-3-[(4-methylphenyl)amino]propyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 483341-26-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(2-aminophenyl)amino]-2-hydroxypropyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 483341-27-1 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(4-aminophenyl)amino]-2-hydroxypropyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 483341-24-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(2-chlorophenyl)amino]-2-hydroxypropyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 483341-25-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[3-[(3-chlorophenyl)amino]-2-hydroxypropyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 483341-28-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[2-hydroxy-3-[[2-(methoxycarbonyl)phenyl]amino]propyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 483341-30-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[2-hydroxy-3-[[4-(methoxycarbonyl)phenyl]amino]propyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 483341-31-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(4-chlorophenyl)-1-[2-hydroxy-3-(phenylamino)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


IT 483341-29-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors)
RN 483341-29-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(1,1-dimethylethyl)-1-[3-[[2-[[1,1-dimethylethyl]amino]carbonyl]phenyl]amino]-2-hydroxypropyl]-4-phenyl- (9CI) (CA INDEX NAME)



IT 506435-42-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors)
RN 506435-42-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-[2-hydroxy-3-(phenylamino)propyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:630290 CAPLUS
DOCUMENT NUMBER: 125:261133
TITLE: Color photographic imaging method
INVENTOR(S): Haijima, Akimitsu; Taniguchi, Masato; Kobayashi, Hidetoshi
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 61 pp.
CODEN: JI00XAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08190182	A2	19960723	JP 1995-18395	19950111
PRIORITY APPLN. INFO.:			JP 1995-18395	19950111



AB A color Ag halide photog. material having on its support >1 hydrophilic colloid layers containing a yellow coupler I (R1 = alkyl, cycloalkyl, aryl, alkoxy, cycloalkoxy, aryloxy, di-substituted amino; R2 = halo, alkoxy, cycloalkoxy, aryloxy, alkyl, dialkylamino; R3 = benzene ring substituent group; X = group releasable on coupling reaction with oxidized developing agent; n = 0-3) whose coupling site has a pKa 6.2-11.0, is color developed with a color developing agent II (R1-6 = H, substituent; R7,8 = substituent; m = 0-3). This imaging method can produce images with good color reproducibility.
IT 102250-85-7
RL: DEV (Device component use); USES (Uses)
(yellow photog. coupler)
RN 102250-85-7 CAPLUS
CN 1H-Pyrrole-3,4-dicarboxylic acid, 1-[1-[[[2-chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]carbonyl]-2-(4-methoxyphenyl)-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1995:750654 CAPLUS
 DOCUMENT NUMBER: 123:156304
 TITLE: Silver halide color photographic material
 INVENTOR(S): Kobayashi, Hidetoshi; Saito, Naoki
 PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.
 CODEN: JK00AF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07134379	A2	19950523	JP 1993-303231	19931110


PRIORITY APPLN. INFO.:
 JP 1993-303231 19931110
 JP 1993-303231 19931110

AB The title Ag halide color photog. material utilizes Ag halide emulsions containing tabular Ag halide grains of aspect ratio 22 and oxycarbonylacetamido-type yellow couplers. The images show high yellow color discrimination, and fogging is inhibited even on long-term storage.

IT 166748-78-3P
 RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (yellow photog. coupler)


RN 166748-78-3 CAPLUS

CN 1H-Pyrrole-3,4-dicarboxylic acid, 1-[1-[[[2-chloro-5-[[dodecylamino)sulfonyl]phenyl]amino]carbonyl]-2-[1-methyl-1-(4-methylcyclohexyl)ethoxy]-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:173220 CAPLUS
 DOCUMENT NUMBER: 122:188124
 TITLE: Synthesis and reactions with DNA of a family of DNA-DNA affinity crosslinking agents
 AUTHOR(S): Sugurdsson, Snorri Th.; Hopkins, Paul B.
 CORPORATE SOURCE: Dep. Chem., Univ. Washington, Seattle, WA, 98195, USA
 SOURCE: Tetrahedron (1994), 50(42), 12065-84
 CODEN: TETRAH; ISSN: 0040-4020
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB DNA-DNA crosslinking agents I [n = 2-4] were prepared. These substances were efficient, sequence selective, DNA-DNA interstrand and intrastrand crosslinking agents. I [n = 2] formed interstrand and intrastrand cross-links at the sequences 5'-d(CGAATT) and 5'-d(GGAATT), resp. The lesions from hydrolysis of the phosphodiester backbones of inter- and intrastrand cross-linked DNA were identical. I [n = 2] was 1000-fold more active as a crosslinking agent than 2,3-bis-(hydroxymethyl)-1-methylpyrrole. The cytotoxicity of I [n = 3] was comparable to cis-DDP.

IT 152574-16-8P 161677-84-5P 161677-85-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and reactions with DNA of bis(hydroxymethyl)pyrrolylalkanoyl distamycin DNA-DNA affinity crosslinking agents)

RN 152574-16-8 CAPLUS


CN 1H-Pyrrole-2,3-dicarboxylic acid, 1-[3-[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-3-oxopropyl]-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 161677-84-5 CAPLUS

CN 1H-Pyrrole-2,3-dicarboxylic acid, 1-[4-[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-4-oxobutyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 161677-85-6 CAPLUS

CN 1H-Pyrrole-2,3-dicarboxylic acid, 1-[5-[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-5-oxopentyl]-, dimethyl ester (9CI) (CA INDEX NAME)


1/27/06

L4 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1994:591157 CAPLUS
DOCUMENT NUMBER: 121:191157
TITLE: Yellow coupler for silver halide photographic material
INVENTOR(S): Takada, Shun; Murali, Kazuhiro
PATENT ASSIGNEE(S): Konalabirou Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXKAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06102637	A2	19940415	JP 1992-253079	19920922
PRIORITY APPLN. INFO.:			JP 1992-253079	19920922
GI				



AB	The title material contains a yellow colorant 1 (R1 = alkyl, cycloalkyl, aryl; R2 = alkyl, cycloalkyl, acyl, aryl; R3 = substituent; n = 0, 1; X1 = group releasable on coupling with oxidized developing agent; Y1 = organic group) with average particle size <150 nm dispersed in a hydrophilic colloid layer. A Ag halide color photog. film using I1 showed good color-reproducibility and uniformity in photog. properties.
IT	157559-84-7 RL: TEM (Technical or engineered material use); USES (Uses) (photog. yellow coupler)
RN	157559-84-7 CAPLUS
CN	1H-pyrrrole-3-carboxylic acid, 1-[1-[[[5-[[2-[[[2,4-bis(1,1-dichloroethyl)propyl]amino]acetyl]amino]-2-cyclopropyl]amino]-2-methoxyphenyl]amino]carbonyl]-2-cyclohexyl-2-oxoethyl], methyl ester (9CI), [CA INDEX NAME]

L4 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1994:457333 CAPLUS
 DOCUMENT NUMBER: 121:57333
 TITLE: Preparation of intermediates for trans-4-hydroxy-6-(2-pyrroloethyl)pyran-2-one HMG-CoA reductase inhibitors
 INVENTOR(S): Butler, Donald E.; Le, Tung V.; Nanninga, Thomas N.
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: U.S., 19 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5298627	A	19940329	US 1993-25701	19930303
US 5423952	A	19940830	US 1993-135385	19931012
CA 2155952	A	19940915	CA 1994-2155952	19940224
CA 2155952	C	19940915		
WO 9420949	A	19940915	WO 1994-US2180	19940224
W1: AU, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
W2: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 6672742	B1	19940926	AU 1994-62742	19940224
US 9407607	B2	19970410		
EP 687263	A1	19951220	EP 1994-910200	19940224
EP 687263	B1	19970730		
R1: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08507521	T2	19960813	JP 1994-520099	19940224
US 3150253	A2	20000322		
HU 75034	B2	19970328	HU 1995-2575	19940224
ES 2166127	E	19970815	AT 1994-910200	19940224
ES 2108435	T3	19971216	ES 1994-910200	19940224
CZ 284365	B6	19981111	CZ 1995-2206	19940224
CZ 285447	B6	19990811	CZ 1998-479	19940224
CZ 285554	B6	19990915	CZ 1998-477	19940224
CZ 285555	B6	19990915	CZ 1998-478	19940224
RU 2138497	C1	19990927	RU 1995-119850	19940224
SK 281109	B6	20001211	SK 1995-1990	19940224
SK 281110	B6	20001211	SK 1999-1339	19940224
SK 281983	B6	20010911	SK 1999-1340	19940224
SK 281984	B6	20010911	SK 1999-1341	19940224
US 5397792	A	19950314	US 1994-243673	19940516
US 5446051	A	19950829	US 1994-332391	19941014
US 5470984	A	19951128	US 1995-374356	19950118
US 5485691	A	19960206	US 1995-440796	19950515
US 5485690	A	19960206	US 1995-440799	19950515
FI 9504048	A	19960422	US 1995-440795	19950515
FI 9504073	A	19950830	FI 1995-4073	19950830
FI 109999	B1	20021115		
NO 9503438	A	19951001	NO 1995-3438	19950501
NO 308529	B1	20000925		
NO 9904708	A	19991122	NO 1999-4708	19990527
NO 308898	B1	20001113		
NO 2000000910	A	20000313	NO 2000-910	20000224
NO 313799	B1	20021202		
FI 2002001437	A	20020802	FI 2002-1437	20020802
FI 2002001438	A	20020802	FI 2002-1438	20020802
PRIORITY APPL. INFO.:			US 1993-25701	A3 19930303

~~1/27/06~~

1/27/06


L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 WO 1994-US2180 W 19940224
 US 1994-243673 A3 19940516
 US 1994-323291 A3 19941014
 US 1995-374356 A3 19950118
 OTHER SOURCE(S): MARPAT 121:57333
 GI




AB Intermediates for title pyranones [I; R1 = 1- or 2-naphthyl, cyclohexyl(methyl), (un)substituted Ph, etc.; R2, R3 = H, (cyclo)alkyl, (un)substituted Ph, cyano, CONH2, etc.; R4 = (cyclo)alkyl, CF3], HMG-CoA reductase inhibitors (no data), were prepared. Thus, (R)-NCH2CH(OH)CH2CO2Et underwent Claisen condensation with AcNPh2 and the reduced product cyclocondensed with Me2C(OMe)2 to give, after further reduction, (4R, cis)-6-(2-aminoethyl)-2,2-dimethyl-N,N-diphenyl-1,3-dioxane-4-acetamide which was cyclocondensed with 4-FCGH4COCHPhCH(COCHMe2)CONHPh to give, after 2 hydrolysis steps, pyrroloheptanoate II (R = 0.5Ca).
 IT 156051-82-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of HMG-CoA reductase inhibitor)
 RN 156051-82-0 CAPLUS
 CN 1H-Pyrrole-1-heptanoamide, 2-(4-fluorophenyl)-8,8-dihydroxy-5-(1-methyl-2-phenyl-1H-pyrrol-3-yl)-4-[(phenylamino)carbonyl]-, [R-(R*, R*)]-(SCI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:99662 CAPLUS
 DOCUMENT NUMBER: 120:99662
 TITLE: Affinity crosslinking of duplex DNA by a pyrrole-oligopeptide conjugate
 AUTHOR(S): Sigurdsson, Snorri T.; Rink, Stacia M.; Hopkins, Paul B.
 CORPORATE SOURCE: Dep. Chem., Univ. Washington, Seattle, WA, 98195, USA
 SOURCE: Journal of the American Chemical Society (1993), 115(26), 12633-4
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB The short DNA sequences identified by clin. useful antitumor substances which act by DNA-DNA crosslinking are present at high frequency in genomes. The therapeutic strategy of targeting lower frequency sites requires the development of affinity crosslinking agents which select longer DNA sequences. The synthesis and in vitro reactions with duplex DNA of the DNA affinity interstrand and intrastrand crosslinking agent I are described. This substance is a conjugate of an oligopeptide which binds non-covalently and sequence specifically in the minor groove of DNA with a 2,3-bis(hydroxymethyl)pyrrole that cross-links duplex DNA by covalent reactions in the minor groove. At concns. as low as 10 nM, I was shown to efficiently interstrand cross-link a linearized plasmid. A comparable extent of reaction with an analog lacking the oligopeptide function (2,3-bis(hydroxymethyl)-1-methylpyrrole) was achieved only with a 1000-fold higher concentration. Using a panel of self-complementary, synthetic DNA duplexes, it was shown that efficient crosslinking was achieved only when a sequence appropriate for non-covalent binding of the oligopeptide was adjacent to sites of covalent reaction for the pyrrole. Specifically, interstrand crosslinking was observed at the sequence 5'-d(CGAATT) and intrastrand crosslinking at the sequence 5'-d(GGAATT). Several lines of evidence suggest that these cross-links bridge the exocyclic amino groups of deoxyguanosine (dG) at 5'-d(CG) (interstrand) and 5'-d(GG) (intrastrand) sequences, including failure of deoxyinosine to substitute for dG in some reactions, depletion of dG in hydrolytic digests of inter- and intrastrand cross-linked samples, and direct observation in the hydrolyzates of a substance with MS properties expected for a conjugate of the crosslinking agent with two dG residues less two equivalent of water.
 IT 152574-16-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deprotection of)
 RN 152574-16-8 CAPLUS
 CN 1H-Pyrrole-2,3-dicarboxylic acid, 1-[3-[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-3-oxopropyl]-, dimethyl ester (SCI) (CA INDEX NAME)

L4 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



1/27/06


L4 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1993:449306 CAPLUS
 DOCUMENT NUMBER: 119:49306
 TITLE: Nonpeptide angiotensin II receptor antagonists. 1. Synthesis and in vitro structure-activity relationships of 4-[[[1H-pyrrol-1-ylacetyl]amino]phenyl]methyl]imidazole derivatives as angiotensin II receptor antagonists
 AUTHOR(S): Sircar, Ila; Winters, R. Thomas; Quin, John, III; Lu, Gina H.; Major, Terry C.; Panek, Robert L.
 CORPORATE SOURCE: Dep. Chem., Parke-Davis Pharm. Res., Ann Arbor, MI, 48105, USA
 SOURCE: Journal of Medicinal Chemistry (1993), 36(12), 1735-45
 CODEN: JMCMAJ; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB A novel series of non-biphenyltetrazole angiotensin II receptor antagonists which contain a 1H-pyrrol-1-ylacetyl residue in place of the benzoyl residue in EXP 6803 have been developed. The receptor binding activity of several members of this new series was in the 10-8 M range, which was better than that of EXP 6803. Introduction of a carboxylic acid moiety at the 2-position of the pyrrole ring enhanced the in vitro binding affinity at the receptor by 10-fold. Compds. containing an acetic acid I (n = 1) or a propionic acid residue I (n = 2) at the 5-position of the imidazole were more potent than the carboxylic acid analog I (n = 0). The binding IC50 of the most potent compound I (n = 2) was 22 nM. I in their best fit conformations were manually overlaid on that of the template conformation of EXP 6803 and EXP 6823, resp. The synthesis and structure-activity relationship data are described.
 IT 142219-18-9P 142245-31-6P 140549-84-2P
 140549-85-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and angiotensin II receptor antagonist activity of)
 RN 142219-18-9 CAPLUS
 CN 1H-Imidazole-5-acetic acid, 2-butyl-4-chloro-1-[[4-[[2-[3-(ethoxycarbonyl)-2-methyl-1H-pyrrol-1-yl]-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1H-Imidazole-5-acetic acid, 2-butyl-4-chloro-1-[[4-[[2-[3-(ethoxycarbonyl)-1H-pyrrol-1-yl]-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 142245-31-6 CAPLUS
 CN 1H-Imidazole-5-acetic acid, 2-butyl-4-chloro-1-[[4-[[2-[3-(ethoxycarbonyl)-2-methyl-1H-pyrrol-1-yl]-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

Absolute stereochemistry.



RN 140549-84-2 CAPLUS
 CN 1H-Imidazole-5-acetic acid, 2-butyl-4-chloro-1-[[4-[[2-[3-(ethoxycarbonyl)-1H-pyrrol-1-yl]-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


Absolute stereochemistry.



RN 140549-85-3 CAPLUS

L4 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1993:29855 CAPLUS
 DOCUMENT NUMBER: 118:29855
 TITLE: Silver halide color photographic material
 INVENTOR(S): Yamada, Kozaburo; Takeuchi, Kiyoshi; Nakagawa, Hajime; Yamamoto, Mitsuru
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04190346	A2	19920708	JP 1990-322052	19901126
JP 2964015	B2	19991018		
PRIORITY APPL. INFO.:			JP 1990-322052	19901126
GI				




AB The title material contains a coupler represented by general structure I. For I, R1 = tert-alkyl, aryl; R2 = halogen, alkoxy, aryloxy, etc.; R3 = a substituent group on benzene ring; 1 = 0 to 4; R4 = a substituent group on pyrrole ring; m = 1 to 4. The title material gives high-quality images.
 IT 145130-92-3P 145130-94-5P
 RL: TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (preparation of, as photog. coupler)
 RN 145130-92-3 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 2,5-dichloro-1-[1-[[[2-chloro-5-[[[dodecyloxy]carbonyl]phenyl]amino]carbonyl]-2-(4-methoxyphenyl)-2-oxoethyl]-4-phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


10651423

1/27/06

L4 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 145130-94-5 CAPLUS
 CN 1H-Pyrrole-3,4-dicarboxylic acid, 1-[[[2-chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]carbonyl]-2-(4-methoxyphenyl)-2-oxoethyl-, diethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1992:469865 CAPLUS
 DOCUMENT NUMBER: 117:69865
 TITLE: Preparation of (imidazolylmethyl)acetanilide derivatives as angiotensin II antagonists
 INVENTOR(S): Sircar, Ila
 PATENT ASSIGNER(S): Warner-Lambert Co., USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9206081	A1	19920416	WO 1991-US6798	19910919
W: AU, CA, CS, FI, HU, JP, KR, NO, SU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
US 5242939	A	19930907	US 1991-757021	19910913
AU 9186538	A1	19920428	AU 1991-86598	19910919
PRIORITY APPL. INFO.:			US 1990-590626	A 19900928
			US 1991-757021	A 19910913
			WO 1991-US6798	A 19910919

OTHER SOURCE(S): MARPAT 117:69865

GI




AB Title compds. I [X, X1 = C, N; R, R1 = H, halo, C1-6 alkyl, alkoxy, carbonyl, carboxyalkyl, trihalomethyl, perfluoroethyl, cyano, CH2CN, alkoxy, methyl, hydroxymethyl, CO2H, etc.; R1 is absent when X = N; RR1 = 5- or 6-membered (substituted) (hetero)aryl ring when X = C; R, R1 = vinyl, C2-10 alkynyl, aryl, heteroaryl, etc.; when X = C; R2 = Fr, Bu, cycloalkyl, allyl, propargyl, SMe, OMe, etc.; R3 = CR4R6; R4 = H, C1-6 alkyl, (substituted) aryl, etc.; when R5 = H; R6 = cyano, CO2H, tetrazolyl, etc.; or R5R6 = CO, C(NOH)] were prepared as angiotensin II antagonists useful as antihypertensives. Thus, L-phenylalanine was

L4 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 cyclocondensed with Me 2,5-dimethoxytetrahydrofuran-2-carboxylate to give 2-(methoxycarbonyl)-o-phenylmethyl-1H-pyrrole-1-acetic acid. This was coupled with 1-[[[4-aminophenyl]methyl]-2-butyl-4-chloro-1H-imidazole-5-methanol (prepn. given) in the presence of 1-hydroxybenzotriazole and DCC to give title compd. (S)-II. The latter was effective at 0.21 μM in vitro in inhibiting binding of 3H-angiotensin II to rat liver membranes.
 142219-18-9P 142219-27-0P 142245-31-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as angiotensin II antagonist)


RN 142219-18-9 CAPLUS
 CN 1H-Imidazole-5-acetic acid, 2-butyl-4-chloro-1-[[[4-[[2-(3-(ethoxycarbonyl)-2-methyl-1H-pyrrol-1-yl]-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142219-27-0 CAPLUS
 CN 1H-Imidazole-5-acetic acid, 2-butyl-1-[[[4-[[2-(3-carboxy-2-methyl-1H-pyrrol-1-yl)-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-4-chloro-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142245-31-6 CAPLUS
 CN 1H-Imidazole-5-acetic acid, 2-butyl-4-chloro-1-[[[4-[[2-(3-(ethoxycarbonyl)-2-methyl-1H-pyrrol-1-yl)-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




1/27/06

L4 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1991:594104 CAPLUS
 DOCUMENT NUMBER: 115:194104
 TITLE: Silver halide color photographic material
 INVENTOR(S): Yoshizawa, Tomomi; Sato, Koichi
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02298943	A2	19901211	JP 1989-119589	19890512
PRIORITY APPLN. INFO.:			JP 1989-119589	19890512
OTHER SOURCE(S):		MARPAT 115:194104		


GI



AB More than 1 emulsion layer of the title photog. material with excellent yellow spectral sensitivity contains oleophilic microparticles dispersion containing 21 yellow coupler I (R = alkyl, cycloalkyl; R1 = alkyl, cycloalkyl, acyl, aryl; R2 = moiety substitutable on benzene ring; n = 1; yr = monovalent ballast moiety; Z = H, moiety capable being released during coupling, reaction) and an aqueous-insol. and organic solvent-soluble polymer compound
 IT 136535-30-3
 RI: USES (Uses)
 (yellow coupler, silver halide color photog. material containing)
 RN 136535-30-3 CAPLUS
 CN 1H-Pyrrole-2,3-dicarboxylic acid, 1-[1-(cyclohexylcarbonyl)-2-[[[5-[[[4-[[[2-(1,1-dimethylethoxy)-5-(1,1,3,3-tetramethylbutyl)phenyl]sulfonyl]amino]butyl]amino]carbonyl]-2-methoxyphenyl]amino]-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



10631423

1/27/06

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

98.01

265.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-14.25

-14.25

STN INTERNATIONAL LOGOFF AT 11:00:14 ON 30 JAN 2006